2016
P-220 To Assess the Rate of Adequate Immune Response to Primary Hepatitis B Vaccination Series in Patients with IBD
Phatak U, Rojas-Velasquez D, Pashankar D. P-220 To Assess the Rate of Adequate Immune Response to Primary Hepatitis B Vaccination Series in Patients with IBD. Inflammatory Bowel Diseases 2016, 22: s76-s76. DOI: 10.1097/01.mib.0000480330.52952.bf.Peer-Reviewed Original ResearchInflammatory bowel diseaseAdequate immune responseType of IBDHep B vaccinationAnti-TNF therapyImmune responseHBsAb levelsVaccination seriesHep BB vaccinationMIU/General populationHepatitis B vaccination seriesYale-New Haven Children's HospitalHepatitis B surface antigenHepatitis B surface antibodyPrimary vaccination seriesPercent of patientsPresence of obesityRetrospective chart reviewHepatitis B vaccineInadequate immune responseUse of immunomodulatorsB surface antigenB surface antibody
2004
Polyethylene Glycol 3350 Without Electrolytes for the Treatment of Functional Constipation in Infants and Toddlers
Loening‐Baucke V, Krishna R, Pashankar D. Polyethylene Glycol 3350 Without Electrolytes for the Treatment of Functional Constipation in Infants and Toddlers. Journal Of Pediatric Gastroenterology And Nutrition 2004, 39: 536-539. DOI: 10.1002/j.1536-4801.2004.tb00904.x.Peer-Reviewed Original ResearchTreatment of functional constipationTreatment of constipationFollow-upFunctional constipationPEG therapyLong-term follow-upShort-term follow-upSafety of PEGDuration of constipationRetrospective chart reviewBody weight/dAdverse effectsLong-term dosingPolyethylene glycol 3350Chart reviewDaily treatmentAverage doseHealthy childrenPhysical examinationNo subjectConstipationDosePEG dosesMonthsShort-term